Business Wire

Connecting the Future with Any Media Communication: NESSUM Alliance's Groundbreaking Technology Incorporated in International Standard IEEE 1901!

Share

In a groundbreaking stride toward advancing communication standards in the digital age, the NESSUM Alliance is proud to announce the release of the IEEE 1901c standard on May 15th. This transformative standard, created from the collaborative efforts of NESSUM's esteemed members, now stands poised to redefine connectivity paradigms worldwide, under the rebranded banner of NESSUM.

With the introduction of IEEE 1901c, formerly known as 'HD-PLC,' NESSUM introduces many new and unparalleled features:

  • Long-Distance Communication: Spanning several kilometers, NESSUM enables a new era of expansive reach.
  • Broadband Communication: Operating in the Mbps class, this standard ensures seamless transmission of data across networks.
  • IP Compatibility: Using standardized Internet Protocol (IP), NESSUM seamlessly integrates with existing infrastructures.
  • Topology-Free Configuration: Facilitating flexible networking, NESSUM overcomes conventional constraints of network configurations.
  • Safety and Security: Prioritizing network and user safety, NESSUM ensures robust and secure communication channels.

Besides high-speed communication on any wire, NESSUM technology also enables the transmission of weak radio signals, facilitating short-range wireless communication applications, including underwater environments. This makes it a truly versatile solution for any media.

The IEEE began the development of the any medium communication standard for IoT applications as IEEE P1901c in May 2022, including the adoption of the Wavelet OFDM method - one of the advanced feature sets of NESSUM's technological advantages compare to other (power line) solutions. After months of effort and refinement, IEEE 1901c attained formal approval in February of this year, marking a monumental leap forward in communication standards.

Mr. Jean-Philippe Faure, Chair of the IEEE 1901WG, lauded the contributions of NESSUM Alliance's expert members, affirming, "This new standard expands the application range of powerline communication to various existing lines and supports low-power radio, opening up new possibilities for high-speed short-range wireless communication."

Agreeing to this sentiment, Mr. Hiroshi Saijo, Head of Business Development & Strategy at Panasonic Holdings Corporation, articulated a shared vision of global proliferation, stating, "We aim to spread this IoT communication standard worldwide as an international standard, not only in products but also in applications."

Mr. Keishi Kajiwara, Director of the Communication Business Division at MegaChips Corporation expressed eager anticipation for market expansion and collaborative endeavors with the new standard, NESSUM's pivotal role in driving innovation.

Mr. Christopher Trabold, CTO and Business Development Leader for Asset Monitoring and Communication at General Electric Vernova, emphasized the burgeoning demand for powerline communication with the digitalization of power infrastructure, signaling a promising trajectory for IEEE 1901c.

IEEE 1901c's transformative capabilities extend to long-distance powerline communication, now covering the several hundred kHz band as NBPLC through innovative resampling. This evolutionary leap finds resonance in diverse sectors, from medium-voltage system control to smart meters, with new applications in Asia and beyond.

Mr. Markus Rindchen, Head of Technology Management at Power Plus Communications AG, pointed out the indispensable role of NESSUM in Germany's Smart Meter Gateway business, underscoring its essential role for the mass roll-out.

Mr. Tomislav Drenski, Marketing Manager at Socionext Europe GmbH is excited to promote the new NESSUM ICs. These advanced ICs offer unique features such as high speed, stable and secure long-distance communication, which surpass other power line solutions available in the market.

With a strong long-term commitment to meet evolving market demands and continuously develop innovation in the IoT landscape, the NESSUM Alliance promotes and supports Any Media communications being inter-operable worldwide. Through a multifaceted approach encompassing webinars, seminars, exhibitions, and extensive promotional activities, the alliance is confident and certain to drive future state-of-the-art solutions with increased compatibility, and lead international standardization efforts.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nessum Alliance Office
info@nessum.org

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release

Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl

FPT and DENSO Sign MOU to Accelerate Software-Defined Vehicle Innovation13.12.2024 06:58:00 CET | Press Release

Global IT corporation FPT and global automotive components manufacturer DENSO signed a Memorandum of Understanding (MOU) to collaborate on advancing software-defined vehicles (SDV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212915049/en/ The signing ceremony took place at DENSO Corporation Aichi Headquarters with the participation of Dr Truong Gia Binh, Chairman of FPT Corporation, Mr Shinnosuke Hayashi, President & CEO of DENSO Corporation, and senior leaders of both companies. (Photo: Business Wire) Under this MOU, the two companies will develop software for next-generation SDVs, with a particular emphasis on mass-production projects for Advanced Driver Assistance Systems (ADAS). Both companies aim to build a high-speed, high-quality global development framework, with plans for expansion by the end of 2027. The partnership is backed by FPT’s two decades of experience in automotive, a global team of 5,000 automotive

Kao Corporation: Regarding Shareholder Statement13.12.2024 05:48:00 CET | Press Release

Oasis Management Company Ltd. (hereinafter referred to as “Oasis Management”), an investment management firm and a shareholder of our company, released a statement regarding Director candidates to be proposed at our 119th Ordinary General Meeting of Shareholders. Kao's Board of Directors and management team strive to increase shareholder value from a long-term perspective based on our business strategy. For the purpose of enhancing our corporate value, we are committed to engaging directly and constructively with all our stakeholders and welcome new perspectives to address challenges. Kao is constantly evolving its selection process to ensure an optimal composition of the Board of Directors. This year, the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members spent more than six months discussing the matter before reaching a final decision, and the decision was made before Oasis Management proposed any director candidates. The timing of the announcem

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor13.12.2024 01:30:00 CET | Press Release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer. “With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we’re eager to explore its potential, particularly in combination with our internally de

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas12.12.2024 23:30:00 CET | Press Release

Takeda (TSE:4502/NYSE:TAK) willhost an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products,” said Christophe Weber, Takeda chief executive officer. “The first three Phase 3 programs will read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years.” Eight Regulatory Filings in FY2025 – FY2029 The late-stage pipeline includes oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), mezagitamab (TAK-079), fazirsiran (TAK-999) and elritercept (TAK-226). Combined these programs have potential peak revenue1 of $10B - $20B. Data from t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye